Bioxyne Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,190.80
201.00
223.80
765.80
1,311.80
Depreciation, Depletion & Amortization
0.30
-
-
1.00
13.60
Other Funds
790.50
122.20
2.50
496.60
110.20
Funds from Operations
400.70
78.90
221.30
268.20
1,188.10
Changes in Working Capital
206.10
245.70
127.50
155.90
667.20
Net Operating Cash Flow
606.80
166.80
348.90
424.00
1,855.40
Capital Expenditures
-
-
-
3.90
171.40
Sale of Fixed Assets & Businesses
175.00
-
-
38.60
-
Net Investing Cash Flow
175.00
-
-
34.70
171.40
Net Financing Cash Flow
-
-
43.70
2,904.70
1,348.60
Net Change in Cash
781.80
33.90
395.10
2,522.30
566.50
Free Cash Flow
606.80
166.80
348.90
428.00
2,026.80
Change in Capital Stock
-
-
43.70
2,904.70
1,348.60
Exchange Rate Effect
-
132.90
2.50
6.90
111.70

About Bioxyne

View Profile
Address
50 Clarence Street
Sydney New South Wales (NSW) 2000
Australia
Employees -
Website http://www.bioxyne.com
Updated 07/08/2019
Bioxyne Ltd. focuses on the development of immune health and immunotherapeutic products. It manufactures, markets, and distributes over-the-counter dietary supplement probiotic products, such as Lactobacillus Fermentum PCC. It operates through the Probiotics and Others segments.